Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.
South Bend, United States. In Biomed Res Int, 2014
Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30-50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthrough CINV.
A blueprint for kinetochores - new insights into the molecular mechanics of cell division.
More papers using
Vienna, Austria. In Nat Rev Mol Cell Biol, 2011
In the past decade, concerted research has resulted in the identification of the individual kinetochore building blocks, the characterization of critical microtubule-interacting components, such as the NDC80 complex, and the development of an approximate model of the architecture of this sophisticated biological machine.
Chlorpromazines and cancer
In Apoptosis, 1971
... Human cervical (HeLa, C33A and Caski) and endometrial (HEC-1-A and KLE) cancer cell lines were maintained in DMEM (Life Technologies, Gaithersburg, MD) and RPMI1640 ...